AUROPHARMA · NSE
Aurobindo Pharma Limited
₹1,734
+2.60% (+₹44)
Prev. close
₹1,690
Volume
12,09,478
Delivery %
56.1%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Aurobindo Pharma Futures, recommending a buy in the ₹1,650-1,700 range with targets at ₹1,800-1,870 and a sto…” | Jay ThakkarICICI Securities | Aurobindo Pharma | PENDING | |
| “Bullish on Aurobindo Pharma, recommending a buy with a target price of ₹1,820 and a stop loss of ₹1,665. The stock is in…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Aurobindo Pharma | PENDING | |
| “Recommends buying Aurobindo Pharma Futures in the ₹1,650-1,660 range, targeting ₹1,740-1,780, with a stop loss below ₹1,…” | Jay ThakkarICICI Securities | Aurobindo Pharma | NOT GRADED |
Fundamentals
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Headquarters
Hyderabad
Employees
29,209
Website
aurobindo.comExchange
View on NSE ↗Key stats
Market cap
₹99,770.53 Cr
P/E ratio (TTM)
27.1
Dividend yield
0.24%
EPS (TTM)
₹64.05
Beta (1Y · daily vs NIFTY 50)
0.35
Beta (5Y · monthly vs NIFTY 50)
0.91
Shares float
27.61 Cr
EPS · quarter ended Jun 2026
₹17.86
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹24,774.63 Cr | ₹23,455.49 Cr | ₹24,855.38 Cr | ₹29,001.87 Cr | ₹31,723.73 Cr | ₹33,653.08 Cr | |
| EBITDA | ₹8,528.83 Cr | ₹4,579.15 Cr | ₹4,009.23 Cr | ₹6,139.99 Cr | ₹7,097.88 Cr | ₹7,272.49 Cr |
| ₹5,335.00 Cr | ₹2,648.15 Cr | ₹1,927.50 Cr | ₹3,172.97 Cr | ₹3,485.88 Cr | ₹3,504.75 Cr | |
| Diluted EPS | ₹91.04 | ₹45.19 | ₹32.9 | ₹54.16 | ₹59.81 | ₹60.34 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹33,853.99 Cr | ₹33,921.72 Cr | ₹39,505.00 Cr | ₹44,717.00 Cr | ₹49,482.00 Cr | ₹58,196.00 Cr | |
| ₹5,339.08 Cr | ₹2,851.27 Cr | ₹5,286.21 Cr | ₹6,647.63 Cr | ₹8,262.87 Cr | ₹8,072.84 Cr | |
| Stockholders' equity | ₹21,929.87 Cr | ₹24,575.98 Cr | ₹26,840.00 Cr | ₹29,843.00 Cr | ₹32,653.00 Cr | ₹37,891.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,328.92 Cr | ₹5,016.48 Cr | ₹2,387.00 Cr | ₹2,435.00 Cr | ₹3,925.00 Cr | ₹5,526.00 Cr | |
| Investing cash flow | ₹598.69 Cr | ₹-3,214.81 Cr | ₹-3,977.75 Cr | ₹-4,255.95 Cr | ₹-1,875.14 Cr | ₹-3,458.43 Cr |
| ₹-1,364.81 Cr | ₹-2,969.27 Cr | ₹1,814.00 Cr | ₹800.00 Cr | ₹120.00 Cr | ₹-1,269.00 Cr | |
| Capital expenditure | ₹-1,873.81 Cr | ₹-2,704.64 Cr | ₹-2,720.00 Cr | ₹-3,562.00 Cr | ₹-2,520.00 Cr | ₹-3,105.00 Cr |
| End cash position | ₹5,373.47 Cr | ₹4,162.51 Cr | ₹4,392.27 Cr | ₹3,385.43 Cr | ₹5,563.79 Cr | ₹7,191.40 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 24(11Q) | Jun 24 | Sep 24–Mar 26(7Q) | Jun 26 |
|---|---|---|---|---|
| Promoter | 51.83% | 51.80% | 51.82% | 51.88% |
| Public | 48.17% | 48.20% | 48.18% | 48.12% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
45 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
The Economic Times · 3 days ago
Aurobindo Pharma shares fall 2% after USFDA issues one observation for Telangana facility
Moneycontrol.com · 3 days ago